Mineralocorticoid Receptor Antagonist Composition for Chronic Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mineralocorticoid receptor antagonists (MRAs) used to treat chronic kidney disease (CKD) are limited by their potential to induce hyperkalemia, leading to elevated serum potassium levels, which can be life-threatening, and exhibit significant individual variation in absorption and efficacy, making it challenging to find a safe and effective dosage for patients with CKD.
Innovation Solution
A pharmaceutical composition containing Compound I, a non-steroid MRA, is developed with a bioavailability of 50% or more, achieved by reducing the particle size of Compound I to 25 μm or less and incorporating surfactants like benzalkonium chloride or sodium dodecyl sulfate, which allows for a safe and effective area under the plasma concentration-time curve (AUC) ranging from 188 ng*h/mL to 3173 ng*h/mL, thereby minimizing the risk of hyperkalemia and individual variation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mineralocorticoid receptor antagonists (MRAs) are used to treat chronic kidney disease, then therapeutic efficacy is improved, but serum potassium levels increase leading to hyperkalemia
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of Compound I, specifically reducing particle size to 25 μm or less and optimizing crystalline form, to achieve controlled bioavailability that maintains therapeutic efficacy while preventing hyperkalemia through predictable serum concentration profiles
Solution Approach 2:
The patent implements partial action by controlling the bioavailability of Compound I to fall within a specific range (50% or more but not complete bioavailability), ensuring sufficient therapeutic effect while avoiding excessive drug exposure that would cause hyperkalemia
2Reliability
If the dosage of MRA is increased to improve therapeutic effect, then efficacy is enhanced, but individual variation in absorption increases making safe dosage determination difficult
Solution Approach 1:
The patent standardizes the bioavailability parameter of Compound I to be 50% or more through particle size reduction and crystalline form optimization, creating a predictable pharmacokinetic profile that reduces inter-individual variation and simplifies dosage determination while maintaining therapeutic efficacy
3Reliability
If particle size of Compound I is reduced to improve bioavailability, then absorption is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent specifies a particle size parameter of 25 μm or less for Compound I, which can be achieved through conventional pharmaceutical processing techniques such as milling and granulation, balancing improved bioavailability with manufacturability using standard equipment and processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition ensures a therapeutic window for Compound I that is both safe and effective in treating CKD by maintaining serum potassium levels within a safe range and reducing individual variation in absorption, thus enhancing clinical safety and efficacy.
Implementation Method 1
incorporating surfactants like benzalkonium chloride or sodium dodecyl sulfate
Data Source
AI summary
Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.